Shortening Treatment Duration for Chronic Hepatitis C
Author Information
Author(s): Andreas Maieron, Sigrid Metz-Gercek, Thomas-Matthias Scherzer, Hermann Laferl, Gabriele Fischer, Martin Bischof, Michael Gschwantler, Peter Ferenci
Primary Institution: Medical University Vienna
Hypothesis
Can a reduced ribavirin dosage of 400 mg/day with a shorter treatment duration of 16 weeks maintain efficacy in patients with chronic hepatitis C genotype 2 and 3?
Conclusion
Shortening the treatment duration with a reduced ribavirin dosage is associated with low sustained virological response rates due to high relapse rates.
Supporting Evidence
- The SVR rate was 51.6% in the 800 mg group and 28.4% in the 400 mg group.
- Patients with low viral load had higher SVR rates compared to those with high viral load.
- The study was terminated early due to inferior outcomes in the lower ribavirin dosage group.
Takeaway
This study looked at how changing the amount of medicine and the length of treatment affects people with a liver infection. It found that using less medicine for a shorter time didn't work as well.
Methodology
Patients were randomized to receive peginterferonα2a with either 800 mg or 400 mg of ribavirin for 16 weeks, and the primary endpoint was sustained virological response (SVR).
Potential Biases
High dropout rates, especially among patients with a history of intravenous drug use, may reflect selection bias.
Limitations
The study was terminated early due to unfavorable results, leading to an uneven distribution of patients across groups.
Participant Demographics
Patients aged 18 to 65 with chronic hepatitis C, genotypes 2 or 3.
Statistical Information
P-Value
0.038
Statistical Significance
p = 0.038
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website